Research
Awards Grant
(CSSC-001) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control( SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 and (CSSC-004) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma)
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide
A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (Therapeutics Studies of Anaplastic Glioma)
A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor
A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma
A Pragmatic Trial to Evaluate the Intermediate-Term Effects of Early, Aggressive Versus Escalation Therapy in People with Multiple Sclerosis
(Traditional versus Early Agressive Therapy for Multiple Sclerosis (TREAT-MS) Trial
A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953
A Prospective Cohort Study of Cryptococcus
A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in
Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)
A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive
Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab:
The "AVIATOR” Study
AMA Reimagining Residency - Creating the Residency Programs of the Future
Adult Brain Tumor Consortium
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Mutiforme
COMPLETED - SPORE in Cervical Cancer - Project 3
COMPLETED - SPORE in Cervical Cancer - Project 4
COMPLETED - SPORE in Cervical Cancer - Project 5
Caregiving and Health Care Utilization After Stroke Among Medicare Beneficiaries
Cell Type Specificity of NF1 Binding Partners and Effects of Variants with Divergent Genotype Phenotype Correlations
Center on Health Services Training and Research (CoHSTAR) New Part Time, Faculty Fellowship
Clot Lysis: Evaluating Acceletrated Resolution of IVH Phase III (The CLEAR III Trial)
Convalescent Plasma Randomized Clinical Trials for SARS-CoV-2 Prophylaxis and Early COVID-19 Treatment are Foundational for Subsequent Hyperimmune Globulin and Vaccines
Copper in the CSF of Patients with Schizophrenia
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas
Effect of Early Weight Bearing on Rehabilitation
Exercise and Body Composition in Juvenile Idiopathic Arthritis
Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media
FIXIT Task Order METRC - Major Extremity Trauma Research Consortium - A Prospective Randomized Trial to Assess Fixation Strategies for Severe Open Tibia Fractures: Modern Ring External Fixators vs. Internal Fixation (FIXIT Study)
Feasibility and Preliminary Effectiveness of a Transdiagnostic Cognitive Behavioral Therapy Treatment Approach for Alcohol Misuse Integrated Within HIV Care in Zambia
Genetic Modifiers of Cystic Fibrosis
HIV Training Through Prevention Training Centers
HOPE in Action: A Clinical Trial of HIV-to-HIV Deceased Donor Kidney Transplantation
HOPE in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation
HPV E5 as a Target for Therapeutics to Treat Precancerous and Benign HPV Lesions
Heart Failure with Preserved EF: Female sex-hormones and cycle GMP-PKG Modula
Hirschsprung Disease Research Collaborative (HDRC)
Hope in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
IMPAACT Network Lab PF Project Specific Task Order - Lab 12 (P1115)
IMPAACT P1115
IMPAACT Protocol P1070 Co-Chair
International Maternal Medicine Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership (P1066)
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1093)
International Maternal Pediatric Adolescent AIDS Clinical Trails (IMPAACT) Group Leadership (P1110)
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1097 and P1101)
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group - P1097A LAB 05
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership
International Maternal Pediatric Adolescent AIDS Clinical Trials Group -- Lab 11
METRC - Major Extremity Trauma Research Consortium
METRC - Major Extremity Trauma Research Consortium
METRC - Major Extremity Trauma Research Consortium - A Prospective Study of Early Mechanical Stabilization and Bleeding in Disruption of the Pelvic Ring
(EMS BIND STUDY
METRC - Major Extremity Trauma Research Consortium - Administrative Core
MISTIE lll: A Phase lll, Randomized, Open-label, 500-subject Clinical Trial of Minimally Invasive Surgery Plus rt-PA in the Treatment of Intracerebral Hemorrhage
Making PROMISE Meaningful to Patients and Providers in Clinical Practice
Mechanisms of Neurodegeneration and Strategies for Neuroprotection in MS
Mechanistic Analyses of a Novel RNA Polymerase I Transcription Checkpoint.
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD
Multicenter Genetic Epigenetic & Expression Analysis of DCIS Outcome Predictors
N0874: Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Neurofibromatosis Type 1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial
Neuromuscular Strain in Chronic Fatigue Syndrome (CFS)
North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD) Johns Hopkins Subcontract
North American AIDS Cohorts on Collaboration and Design (NAACCORD)
OUTLET Task Order METRC - Major Extremity Trauma Research Consortium - Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage vs. Transtibial Amputation Protocol (OUTLET Study)
POVIV Task Order METRC - Major Extremity Trauma Research Consortium - A Prospective Randomized Trial to Assess PO versus IV Antibiotics for the Treatment of Early Post-op Wound Infection after Extremity Fractures (POvIV)
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)
Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
Phase I/II Study of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients with Newly Diagnosed Malignant Glioma
Phase I/II Trial of Temozolomide and ABT-888 in Subjects with Newly Diagnosed
Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma
Phase O/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Prospective Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
SPORE in Cervical Cancer
SPORE in Cervical Cancer
SPORE in Cervical Cancer
SPORE in Cervical Cancer
SPORE in Cervical Cancer - Administrative Core
SPORE in Cervical Cancer - Administrative Core
SPORE in Cervical Cancer - Biostatistics Core
SPORE in Cervical Cancer - Career Enhancement Program
SPORE in Cervical Cancer - Cervical SPORE Pilot Project (Charles Leath)
SPORE in Cervical Cancer - Core A: Administrative Core
SPORE in Cervical Cancer - Core B (Biostatical)
SPORE in Cervical Cancer - Core B: Biostatistics and Bioinformatics Core
SPORE in Cervical Cancer - Core C (Tissue)
SPORE in Cervical Cancer - Core C: Tissue/Pathology Core
SPORE in Cervical Cancer - Core D (Career Development)
SPORE in Cervical Cancer - Creating a Cervical Cancer Cell Line Genomics Encyclopedia
SPORE in Cervical Cancer - Developmental Research Program
SPORE in Cervical Cancer - Pilot Project: An Assessment of Immunogenicity in Adolescent Women receiving Gardasil, Gardasil 9, or Cervarix
SPORE in Cervical Cancer - Pilot Project: T-cell Mediated Immunity in TC-1 Tumor Bearing Mice Treated by Sequential Radiation and Therapeutic ANAX5-E7 Protein
SPORE in Cervical Cancer - Project 1
SPORE in Cervical Cancer - Project 1
SPORE in Cervical Cancer - Project 1: Heat Stable RG1-VLPs, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer
SPORE in Cervical Cancer - Project 2
SPORE in Cervical Cancer - Project 2
SPORE in Cervical Cancer - Project 2: DNA Prime-protein Boost Vaccination to treat HPV16 Infection in Women with ASC-US or LSIL
SPORE in Cervical Cancer - Project 3
SPORE in Cervical Cancer - Project 3: Electroporation Delivery of pNGVL4aCRTE6E7L2 DNA for treatment of HPV16+ CIN2/3 Patients
SPORE in Cervical Cancer - Project 4
SPORE in Cervical Cancer - Project 4: A Phase I Safety and Immunogenicity Study of an HPV16-Specific Therapeutic Protein, TA-CIN, Administered Intraumorally during
SPORE in Cervical Cancer - Project 5
SPORE in Cervical Cancer - Tissue Core
SPORE in Cervical Cancer - Tissue Core
STREAM Task Order METRC - Major Extremity Trauma Research Consortium - Streamlining Trauma Research Evaluation with Advanced Measurement (STREAM Study)
Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma
TBCRC -AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer
TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)
TBCRC 029_Clinical and Biological Characterization of Male Breast Cancer
TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)
TBCRC 040: Pathologic Response Evaluation & Detection In Circulating Tumor DNA (PREDiCT DNA)
TBCRC 042 UAB 1905: A Randomized, Phase II, Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
TBCRC 048 UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes
TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
TBCRC-AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer
TBCRC017: The Correlation of Radiographic Complete Response on Breast MRI with Pathologic Complete Response in Patients Receiving Neoadjuvant Systemic Treatment
TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
TBCRC034: The Incidence of Adjacent Synchronous lpsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with lntraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
The Association of Allergic Disease with Clinical Outcomes in COPD
The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide
Transitions to Family Caregiving and Its Impact on Health Indicators
UAB 1017/TBCRC 008: A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and nab-Paclitaxel (CP)With or Without Vorinostat as Preoperative Chemotherapy in HER-2 Negative Primary Operable Breast Cancer
UAB 1017/TBCRC 008:A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in Her2-Negative Primary Operable Breast Cancer
UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study
UAB 1019/TBCRC 015: Investigation of Genetic Determinants of Capecitabine Toxicity
UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
UAB 1052-TBCR020: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Lobular Neoplasia of the Breast by Core Needle Biopsy
UAB 1527 – A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer
UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes
VANCO Task Order METRC - Major Extremity Trauma Research Consortium - Local Antibiotic Therapy to Reduce Infection after Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression
XUAB 2023-IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated with NeoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT Study
